IM
IMMX.US Immix Biopharma Inc
- Market cap
- USD 657M
- P/E
- -
- P/B
- 1.96x
- ROE
- -14.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMMX.US undervalued?
Graham numberThe Graham number of Immix Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immix Biopharma Inc fundamental analysis
No fundamental analysis for Immix Biopharma Inc yet.
Immix Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Full company profileImmix Biopharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immix Biopharma Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | -89.5M | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -1.08K | -2.32K | -2.47K | -89.5M | -5.47K | -115K | -365K | - |
| Operating Income | -842K | -454K | -1.35M | -8.22M | -16.1M | -22.7M | -30.0M | -52.3M |
| EBITDA | -841K | -452K | -24.2M | -8.22M | -15.6M | -21.5M | -29.6M | -47.9M |
| Net Income | -973K | -1.15M | -24.4M | -8.23M | -15.4M | -21.6M | -29.4M | -47.4M |
| EPS | -0.29 | -0.15 | -6.64 | -0.59 | -0.89 | -0.76 | -0.89 | -0.64 |
| Balance Sheet | ||||||||
| Total Assets | 943K | 540K | 18.2M | 14.9M | 19.9M | 22.9M | 105M | 346M |
| Total Liabilities | 4.59M | 5.27M | 202K | 1.75M | 3.72M | 9.70M | 11.0M | 10.9M |
| Shareholders' Equity | -3.65M | -4.73M | 18.0M | 13.2M | 16.4M | 13.3M | 93.8M | 335M |
| Cash & Short-term Investments | 734K | 391K | 17.6M | 13.4M | 17.5M | 17.7M | 100M | 336M |
| Total Debt | 4.10M | 4.10M | 50.0K | - | - | 1.07M | 1.07M | 965K |
| Cash Flow | ||||||||
| Operating Cash Flow | -790K | -405K | -1.59M | -7.41M | -11.4M | -14.6M | -23.9M | -45.2M |
| Capital Expenditure | 7.31K | 4.00 | 802.00 | 3.00 | 52.1K | 1.18M | 733K | 233K |
| Free Cash Flow | -797K | -405K | -1.59M | -7.41M | -11.4M | -15.8M | -24.7M | -45.4M |
| Ratios | ||||||||
| ROE | - | - | -135.5% | -62.5% | -94.0% | -163.1% | -31.4% | -14.2% |
| ROA | -103.2% | -212.7% | -134.0% | -55.2% | -77.4% | -94.2% | -28.1% | -13.7% |
| Debt to Equity | - | - | 0.00x | - | - | 0.08x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immix Biopharma Inc dividends
Immix Biopharma Inc has not paid dividends in the last 7 fiscal years.
Who owns Immix Biopharma Inc
- Insiders 14.85%
- Institutions 74.62%
- Public & others 10.54%
- Shares outstanding 83.8M
- Free float 68.4M
Top funds holding IMMX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 3.89M | 4.64% | +52.65% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.24M | 2.67% | +25.64% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.21M | 2.63% | +2.69% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 1.95M | 2.32% | +34.14% | Jun 2026 |
| iShares Russell 2000 ETF | 1.50M | 1.79% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.14M | 1.36% | +86.62% | Sep 2026 |
| Columbia Small Cap Growth Inst | 986K | 1.18% | +31.58% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 842K | 1.01% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 824K | 0.98% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 698K | 0.83% | 0.00% | Oct 2026 |
| AB Small Cap Growth A | 648K | 0.77% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 645K | 0.77% | +80.68% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 558K | 0.67% | -0.38% | Oct 2026 |
| Columbia Small Cap Value Discv A | 490K | 0.58% | +0.74% | Sep 2026 |
| HR SICAV - Global Quant Equits - (GBP) A | 461K | 0.55% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 451K | 0.54% | +0.46% | Aug 2026 |
| Vanguard Russell 2000 ETF | 347K | 0.41% | +47.08% | Sep 2026 |
| abrdn Life Sciences Investors | 340K | 0.41% | +25.97% | Oct 2026 |
| Fidelity Extended Market Index | 280K | 0.33% | -2.44% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 254K | 0.30% | -0.54% | Oct 2026 |
Top institutions holding IMMX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 9.78M | 11.67% | 0.00% | Jun 2026 |
| Saturn V Capital Management LLC | 4.66M | 5.56% | +26.12% | Jun 2026 |
| Eventide Asset Management, LLC | 3.89M | 4.64% | +52.65% | Jun 2026 |
| State Street Corp | 3.00M | 3.58% | +1,461.64% | Jun 2026 |
| BlackRock Inc | 2.99M | 3.57% | +538.37% | Jun 2026 |
| Deep Track Capital, LP | 2.78M | 3.31% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.51M | 2.99% | +40.22% | Jun 2026 |
| Opaleye Management Inc | 2.35M | 2.80% | 0.00% | Jun 2026 |
| Millennium Management LLC | 2.07M | 2.47% | +18.07% | Jun 2026 |
| UBS Group AG | 1.94M | 2.32% | +2,427.35% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.79M | 2.14% | +9.34% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.74M | 2.08% | +319.26% | Jun 2026 |
| Wellington Management Company LLP | 1.47M | 1.76% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 1.28M | 1.52% | +265.04% | Jun 2026 |
| Geode Capital Management, LLC | 1.20M | 1.43% | +159.20% | Jun 2026 |
| Velan Capital Investment Management LP | 1.09M | 1.29% | +46.62% | Jun 2026 |
| Bleichroeder LP | 1.00M | 1.19% | 0.00% | Jun 2026 |
| Logos Global Management LP | 1.00M | 1.19% | -18.37% | Jun 2026 |
| Franklin Templeton Inc | 969K | 1.16% | +0.01% | Jun 2026 |
| Aberdeen Group PLC | 819K | 0.98% | 0.00% | Sep 2026 |
Immix Biopharma Inc company profile
- Company name
- Immix Biopharma Inc
- Ticker
- IMMX.US
- Exchange
- USA Stocks
- Listed since
- Dec 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
- Phone
- 310 651 8041
- Website
- immixbio.com
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma Inc management
7- Dr. Ilya Rachman M.B.A., M.D., Ph.D.Co-Founder, CEO, Chief Scientific Officer & Chairman · born 1973
- Mr. Gabriel Morris B.A.President, CFO & Director · born 1987
- Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.Scientific Co-Founder · born 1947
- Dr. Graham Ross FFPM, M.D.Chief Medical Officer & Head of Clinical Development · born 1960
- Dr. David Marks MBBS, Ph.D.Chief Medical Officer of Cell Therapy
- Mr. Mel Davis-PickettHead of CMC Technical Development
- Mr. Michael A. GrabowChief Commercial Officer